relationships, or among individuals with HIV infectionrequires measured clinical judgment until further studies are available. Furthermore, the vexed question remains of whether the notable reduction in transmission provided by valaciclovir would be achieved by other antiviral drugs, such as aciclovir or famciclovir, and if so, at what dose? Without comparative data, individual prescribing decisions in specific healthcare settings will need to be made on the basis of factors including availability, potential adherence, and cost.
No takes yet. Share an insight, caveat, or question.
Owen et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: